CIK 0001738021 · Non-accelerated filer<br>Smaller reporting company
Compass Therapeutics, Inc.
Sign in to watch- Ticker
- CMPX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-500-8099
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Former names
- Olivia Ventures, Inc.
- Open-market buys, last 90 days
- $21,250
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$21,250. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-10 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +10,000 | $3.37 | $34K | 6,021,873 |
| 2023-02-27 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +20,000 | $3.98 | $80K | 6,011,873 |
| 2023-02-15 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +20,000 | $3.86 | $77K | 5,991,873 |
| 2023-02-08 | WURZER DAVID M Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-02-08 | Chiniara Ellen Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2023-02-08 | GRAY MARY ANN Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2023-02-08 | Ferneau Philip Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-02-08 | GORDON CARL L Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2023-02-08 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Grant or award | +500,000 | 5,971,873 | ||
| 2023-02-08 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2023-02-08 | Bisker-Leib Vered Chief Operating Officer | Grant or award | +400,000 | 1,484,914 | ||
| 2023-02-08 | Bisker-Leib Vered Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2023-01-31 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +20,000 | $4.05 | $81K | 5,471,873 |
| 2023-01-24 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +20,000 | $4.19 | $84K | 5,451,873 |
| 2022-11-25 | Bisker-Leib Vered Chief Operating Officer | Sale | −2 | $4.36 | $9 | 1,060,414 |
| 2022-11-23 | Bisker-Leib Vered Chief Operating Officer | Sale | −9,569 | $4.30 | $41K | 1,060,416 |
| 2022-11-22 | Bisker-Leib Vered Chief Operating Officer | Sale | −14,929 | $4.19 | $63K | 1,069,985 |
| 2022-11-21 | Bisker-Leib Vered Chief Operating Officer | Sale | −16,035 | $4.34 | $70K | 1,084,914 |
| 2022-11-18 | Bisker-Leib Vered Chief Operating Officer | Sale | −6,226 | $4.40 | $27K | 1,107,175 |
| 2022-11-08 | ORBIMED ADVISORS LLC Director | Purchase | +402,000 | $3.21 | $1.3M | 15,219,994 |
Page 4 of 8 · 143 trades